南财智讯1月29日电，利德曼发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为亏损 1500万元—2800万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏损2400万 元—3700万元。报告期内，受国内诊断试剂集采品种扩面、DRG/DIP政策进一步执行实施以及行业竞争 加剧等影响，公司主营业务收入和诊断试剂产品毛利率同比下降，导致公司归属于上市公司股东的净利 润为亏损。本期预计非经常性损益对净利润的影响金额约为900万元，主要为政府补助、公允价值变动 收益等。上年同期非经常性损益对净利润的影响金额为2237万元。 ...

利德曼公告，预计2025年度净利润亏损1500万元–2800万元，上年同期亏损7510.13万元。本期预计非经 常性损益对净利润的影响金额约为900万元，上年同期非经常性损益对净利润的影响金额为2237万元。 报告期内，受国内诊断试剂集采品种扩面、DRG/DIP政策进一步执行实施以及行业竞争加剧等影响，公 司主营业务收入和诊断试剂产品毛利率同比下降，导致公司归属于上市公司股东的净利润为亏损。 ...

证券代码：300289 证券简称：利德曼 公告编号：2026-006 北京利德曼生化股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、本次重大资产重组的基本情况 北京利德曼生化股份有限公司（以下简称"公司"或"上市公司"） 正在筹划以支付现金方式收购北京先声祥瑞生物制品股份有限公司 （以下简称"目标公司"）部分股东持有的目标公司合计不超过 70%的 股份（以下简称"本次交易"）。本次交易前，公司未持有目标公司的 股份；本次交易完成后，公司将取得目标公司控制权，目标公司将成 为公司的控股子公司。 根据初步测算，本次交易预计构成《上市公司重大资产重组管理 办法》规定的重大资产重组。本次交易不涉及上市公司发行股份，不 构成关联交易，也不会导致公司控制权变更。 二、本次重大资产重组的披露情况 2025 年 7 月 30 日，公司与目标公司、目标公司股东上海百家汇 投资管理有限公司（已于 2025 年 12 月 24 日更名为"海南百迈投资有 限公司"）、海南先声百家汇科技发展有限公司、南京百佳瑞企业管理 咨询合伙企业（有 ...

Financial Performance - The company expects a net loss of between RMB 15 million and RMB 28 million for the fiscal year 2025, compared to a net loss of RMB 75.1 million in the same period last year [3]. - The net profit after deducting non-recurring gains and losses is projected to be a loss between RMB 24 million and RMB 37 million, compared to a loss of RMB 97.5 million in the previous year [3]. - The estimated impact of non-recurring gains and losses on net profit for the current period is approximately RMB 9 million, primarily from government subsidies and fair value changes, compared to RMB 22.37 million in the same period last year [5]. Business Challenges - The decline in main business revenue and gross margin of diagnostic reagent products is attributed to the expansion of domestic diagnostic reagent centralized procurement, further implementation of DRG/DIP policies, and intensified industry competition [5].

Group 1 - The Nipah virus outbreak in India has led to increased attention on related concept stocks, with several companies responding urgently to the situation [1] - Companies such as Capbio and Daan Gene have reported significant stock price increases, with Capbio rising by 20% and Daan Gene by 9.99% as of January 27 [2] - Various A-share listed companies are disclosing their technology and product layouts related to Nipah virus testing, including Wanfu Bio and Shengxiang Bio, which have developed specific testing kits [3][4] Group 2 - Capbio has developed a Nipah virus nucleic acid testing kit using fluorescence PCR technology, providing essential support for global quarantine and disease control monitoring [4] - Wanfu Bio has launched different product forms of the Nipah virus nucleic acid testing kit, compatible with its molecular POCT platform and other PCR systems [3] - Some companies, such as Hualan Biological and others, have clarified that they do not have any business related to Nipah virus vaccines or products [5][6]

Group 1 - The Nipah virus outbreak in India has raised concerns, particularly in West Bengal, but its impact on China is considered minimal as no cases have been reported in the country [1] - The market has shown increased interest in stocks related to virus prevention and diagnostics, with companies like Capbio and Da'an Gene experiencing significant stock price increases [1] - The Nipah virus has a transmission period of 3 to 14 days, with initial symptoms resembling influenza, making early detection crucial for effective intervention [1] Group 2 - Several A-share listed companies have announced their developments in Nipah virus detection technologies, including Wanfu Bio and Shengxiang Bio, which have launched various testing kits [3][5] - Capbio has developed a Nipah virus nucleic acid detection kit, providing essential support for global quarantine and disease control monitoring [5] - Some companies, such as Hualan Vaccine and Yirui Bio, have clarified that they do not have any products related to Nipah virus prevention or treatment [5][6]

Group 1 - The core point of the news is that Lidman experienced a decline of 5.06% in its stock price, reaching 7.31 CNY per share, with a trading volume of 73.24 million CNY and a turnover rate of 1.81%, resulting in a total market capitalization of 3.977 billion CNY [1] - Lidman is based in Beijing Economic and Technological Development Zone and was established on November 5, 1997, with its listing date on February 16, 2012. The company's main business includes in vitro diagnostic reagents (67.84%), diagnostic instruments (14.17%), other services (13.21%), and biochemical raw materials (4.78%) [1] Group 2 - From the perspective of Lidman's top ten circulating shareholders, a fund under Yongying Fund ranks among them. The Medical Device ETF (159883) entered the top ten circulating shareholders in the third quarter, holding 2.0113 million shares, which accounts for 0.37% of the circulating shares. The estimated floating loss today is approximately 784,400 CNY [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 3.677 billion CNY. Year-to-date returns are 9.26%, ranking 1688 out of 5548 in its category, while the one-year return is 14.72%, ranking 3691 out of 4285. Since its inception, it has incurred a loss of 46.69% [2] Group 3 - The fund manager of the Medical Device ETF (159883) is Chu Kefa, who has been in the position for 2 years and 168 days. The total asset scale of the fund is 5.205 billion CNY, with the best fund return during the tenure being 103.17% and the worst being -30.27% [3]

证券日报网讯 1月22日，利德曼在互动平台回答投资者提问时表示，截至2026年1月20日收盘，公司股 东人数为31371户。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Lideman (300289) reported its shareholder count as of January 9, 2026, which stands at 31,517 households [1]

Core Viewpoint - The assessment of Xiansheng Xiangrui's valuation and the rationale behind the acquisition by Beijing Lideman Biochemical Co., Ltd. is deemed reasonable, with a valuation increase rate of 162.23%, which is lower than the average in the biopharmaceutical industry [1][6]. Group 1: Performance Forecast - Xiansheng Xiangrui is projected to achieve a revenue of 582.35 million yuan in 2024, a decrease of approximately 10% year-on-year, with a net profit of 180.14 million yuan, down 14.39% [2]. - The decline in performance is attributed to adjustments in sales models, fiscal constraints in certain regions, and intensified local market competition, although terminal sales are expected to continue growing [2]. - The company is expected to see a non-simulated net profit of 158.76 million yuan in 2024, representing a year-on-year growth of 18.3% [2]. - The market for tuberculosis prevention remains significant, with 696,000 new patients expected in 2024, and the market size for the relevant segment is projected to grow from 2.8 billion yuan in 2024 to 3.5 billion yuan by 2030, with a compound annual growth rate of 4.01% [2]. Group 2: Product and Market Position - Xiansheng Xiangrui's core product, TB-PPD, holds an approximate market share of 83.9% in the skin test market for 2024 [3]. - The company’s IGRA product is expected to be approved and sold by 2025, with other pipeline products like Xs02 progressing well and anticipated to launch by 2027 [3]. - The revenue growth forecast for 2025-2030 is a compound annual growth rate of 3.59%, which is cautious and lower than the industry growth rate [3]. Group 3: Valuation Methodology - The selection of comparable companies in the vaccine industry for market-based assessment is justified, as Xiansheng Xiangrui's core products are similar in management and sales models to vaccine companies [4]. - The assessment process involved selecting four comparable companies from 54 listed bioproduct companies, excluding competitors with a high proportion of agency business [4]. Group 4: Asset Divestiture - The decision to divest mRNA-related assets is considered reasonable, as the company had not achieved marketable R&D results from its mRNA technology platform investment of 41.41 million yuan [5]. - The asset was sold for 83.18 million yuan, generating an investment return of 11.62 million yuan, which is beneficial for focusing on core business and protecting shareholder interests [5]. Group 5: Fairness of Transaction Pricing - The total equity valuation of Xiansheng Xiangrui is assessed at 2.674 billion yuan, with a valuation increase rate of 162.23%, which is within a reasonable range compared to the average increase rate of 338.56% in recent biopharmaceutical transactions [6]. - The final transaction price for 70% of the shares is 1.733 billion yuan, aligning closely with the assessment results, confirming the fairness of the pricing [6].